OrthoPediatrics

OrthoPediatrics (Nasdaq:KIDS) this week posted first-quarter results that beat the overall consensus on Wall Street.

The Warsaw, Indiana-based company reported losses of $9.1 million, or -47¢ per share, on sales of $23.4 million for the three months ended March 31, for a bottom-line gain of 12.3% on sales growth of 9.11% compared with Q1 2021.

Adjusted to exclude one-time items, earnings per share were -30¢, 7¢ ahead of The Street, where analysts were looking for sales of $22.75 million.

“I am extremely proud of our team and what they were able to accomplish to start the year strong despite the impact of Omicron in January and February,” President and CEO David Bailey said in a news release. We announced a limited launch of our new PediFlex Advanced Interlocking Clamp, received an additional FDA clearance for Drive Rail, our external fixation system and also made significant progress on multiple R&D projects. Additionally, our recent acqu…

OrthoPediatrics (NSDQ:KIDS) this week posted third-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates.

The Warsaw, Indiana-based orthopedics company reported losses of -$2.2 million, or -11¢ per share, on sales of $25.1 million for the three months ended Sept. 30, for a sales growth of 12.94% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were -15¢, 13¢ ahead of The Street, where analysts were looking for sales of $26.28 million.

“We are proud to report double-digit growth despite the temporary impact of COVID, RSV, and hospital staffing shortages. International growth was particularly strong indicating continued recovery of these markets. We continue to make substantive progress in advancing our key strategic initiatives, including securing enabling technologies and sponsoring multiple key clinical education events,” president and CEO David Bailey said in a news release.

OrthoPediatrics (NSDQ:KIDS) today said it launched its Response neuromuscular scoliosis system.

The Warsaw, Ind.–based company designed the system to treat pediatric patients who have neuromuscular scoliosis. It has a complete set of implants and instruments to simplify insertion and has specific options to address extreme hyperlordosis and sacral/pelvic fixation.

“Neuromuscular scoliosis patients can present with a wide array of extreme 3-dimensional deformities, which can require highly individualized and complicated surgical treatment. The addition of the neuromuscular scoliosis system to the OrthoPediatrics Response offering was designed to improve the speed and efficacy of the instrumentation, correction and stabilization of these complicated deformities, with the aim of optimizing outcomes. This now makes the OP Response system the ideal one for all types of pediatric spinal deformity,” Scott Luhmann, pediatric orthopedic surgeon and chief of …

OrthoPediatrics (NSDQ:KIDS) yesterday posted first-quarter results that beat the overall consensus on Wall Street and increased its full-year guidance.

The Warsaw, Ind.-based company reported losses of -$10.4 million, or -54¢ per share, on sales of $21.5 million, for the three months ended March 31, for a sales growth of 31.2% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were -25¢, 2¢ ahead of The Street, where analysts were looking for sales of $19.86 million.

“The company’s first-quarter results reflect the resilience of our business, steady execution of our strategy and the unwavering dedication of our team. With revenue growth exceeding 30% year-over-year, adjusted EBITDA and gross margins continuing to improve, and meaningful progress across all product categories, OrthoPediatrics is well-positioned for sustained growth as we advance toward recovery from the COVID-19 pandemic. We are particularly encouraged by the 19…

OrthoPediatrics (NSDQ:KIDS) posted fourth-quarter results that missed the consensus forecast on Wall Street.

The Warsaw, Ind.-based company reported losses of -$14 million, or -73¢ per share, on sales of $18.9 million for the three months ended Dec. 31, 2020, for a sales loss of -0.15% compared with Q4 2019.

Earnings per share were -73¢ per share, 46¢ behind The Street where analysts were looking for sales of $20.5 million and earnings of -27¢ per diluted share.

“Despite COVID-19, in 2020 we continued the systematic execution of our growth initiatives both domestically and internationally. Elective surgery volumes declined globally but staged a gradual recovery throughout the year. Second-quarter sales declined 25% but then began to recover with third-quarter sales growth of 7% and a 0.1% fourth-quarter sales decline due to the $2.7 million reduction which impacted fourth-quarter revenue growth by 14%,” CEO Mark Throdahl said in a news release.